AGN Stock Overview
Operates as a clinical stage pharmaceutical development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Algernon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.075 |
| 52 Week High | CA$0.17 |
| 52 Week Low | CA$0.06 |
| Beta | -0.43 |
| 11 Month Change | -11.76% |
| 3 Month Change | -34.78% |
| 1 Year Change | 7.14% |
| 33 Year Change | -94.00% |
| 5 Year Change | -93.68% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -6.3% | 10.1% | 0.2% |
| 1Y | 7.1% | -19.0% | 21.0% |
Return vs Industry: AGN exceeded the Canadian Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: AGN underperformed the Canadian Market which returned 21% over the past year.
Price Volatility
| AGN volatility | |
|---|---|
| AGN Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: AGN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: AGN's weekly volatility has decreased from 19% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Chris Moreau | algernonpharmaceuticals.com |
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company’s pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries.
Algernon Pharmaceuticals Inc. Fundamentals Summary
| AGN fundamental statistics | |
|---|---|
| Market cap | CA$2.04m |
| Earnings (TTM) | -CA$2.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs AGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.61m |
| Earnings | -CA$2.61m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AGN perform over the long term?
See historical performance and comparison